Neoadjuvant mitomycin C showed a favorable safety profile with mild to moderate side effects, including hematuria, dysuria, and itchy scalp. The trial did not show significant improvement in 12-month ...

UGN-102 is UroGen’s sustained-release formulation of mitomycin being developed for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

Treatment strategies for UTUC depend on tumor grade and location, with options including radical nephroureterectomy, segmental ureterectomy, and mitomycin gel. Accurate diagnosis and risk ...

WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today ...

Institute for Stroke and Dementia Research (ISD), LMU University Hospital, LMU Munich, Munich 81377, Germany Normandie University, UNICAEN, INSERM UMR-S U1237, Physiopathology and Imaging of ...

Gemcitabine and mitomycin are the drugs used most often for intravesical chemotherapy. Researchers are also studying newer ways of delivering these drugs that might help them work better (see What’s ...

Similar to what other NICUs have found, treatment of extravasation injuries in our NICU was unstandardized and varied greatly. [2,9] Documentation of the date and time of injury as well as wound ...